Handbook of targeted cancer therapy /:
Make optimal use of the latest personalized therapeutic strategies with Handbook of Targeted Cancer Therapy! This concise, practical oncology reference examines more than 120 targeted therapy agents for which clinical trial data are available, and explains when and how you can use them to most effec...
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Philadelphia :
Wolters Kluwer Health,
©2015.
|
| Ausgabe: | 1st ed. |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Make optimal use of the latest personalized therapeutic strategies with Handbook of Targeted Cancer Therapy! This concise, practical oncology reference examines more than 120 targeted therapy agents for which clinical trial data are available, and explains when and how you can use them to most effectively combat cancer. Approach clinical challenges from any direction with separate sections on Targets by Organ Site, Carcinogenesis from the Perspective of Targeted Therapy, Molecular Targets and Pathways, and Targeted Therapy Agents; find information easily thanks to a color-coded format and an intuitive organization; access the complete contents online and on mobile devices, with regular updates to include newly approved treatments and important state of the art cancer information for caregivers, researchers, other health care professionals, and even patients. Now with the print edition, enjoy the bundled interactive eBook edition, offering tablet, smartphone, or online access to: complete content with enhanced navigation; a powerful search tool that pulls results from content in the book, your notes, and even the web; cross-linked pages, references, and more for easy navigation; highlighting tool for easier reference of key content throughout the text; ability to take and share notes with friends and colleagues and quick-reference tabbing to save your favorite content for future use. |
| Beschreibung: | 1 online resource (xix, 287 pages) : color illustrations |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781451193268 1451193262 9781469894584 1469894580 |
Internformat
MARC
| LEADER | 00000cam a2200000Ma 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn904377433 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 140722s2015 paua obf 001 0 eng d | ||
| 040 | |a OTZ |b eng |e pn |c OTZ |d OCLCO |d EBLCP |d OCLCF |d OCLCQ |d YDX |d N$T |d OCLCO |d UAB |d OCLCO |d OCLCA |d D6H |d OCLCO |d AGLDB |d OCLCO |d IGB |d OCLCO |d CN8ML |d SNK |d INTCL |d OCLCO |d MHW |d BTN |d AUW |d OCLCQ |d VTS |d OCLCQ |d OCLCO |d AU@ |d G3B |d S8I |d S8J |d S9I |d STF |d LOA |d MERUC |d SCB |d OCLCO |d VT2 |d USU |d OCLCO |d OCLCQ |d OCLCA |d OCLCQ |d OCLCA |d VLY |d DKU |d YDXCP |d QGK |d OCL |d OCLCO |d OCLCQ |d OCLCO |d ELBRO |d OCLCQ |d OCLCO |d OCLCL |d OCLCQ | ||
| 016 | 7 | |a 101637430 |2 DNLM | |
| 019 | |a 899359538 |a 987351660 |a 987738124 |a 1072012677 |a 1103263051 |a 1162302923 |a 1228572739 | ||
| 020 | |a 9781451193268 |q (alk. paper) | ||
| 020 | |a 1451193262 |q (alk. paper) | ||
| 020 | |a 9781469894584 | ||
| 020 | |a 1469894580 | ||
| 020 | |z 1451193262¡ | ||
| 035 | |a (OCoLC)904377433 |z (OCoLC)899359538 |z (OCoLC)987351660 |z (OCoLC)987738124 |z (OCoLC)1072012677 |z (OCoLC)1103263051 |z (OCoLC)1162302923 |z (OCoLC)1228572739 | ||
| 050 | 4 | |a RC271.C5 |b H36 2015 | |
| 050 | 4 | |a RC271.C5 | |
| 060 | 4 | |a QZ 39 |b H23658 2015 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 7 | |a 616.99/4061 |2 23 | |
| 082 | 7 | |a RC271.C5 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Handbook of targeted cancer therapy / |c editors, Daniel D. Karp, Gerald S. Falchook ; assistant editor, Johnique T. Atkins. |
| 246 | 3 | |a Targeted cancer therapy | |
| 250 | |a 1st ed. | ||
| 260 | |a Philadelphia : |b Wolters Kluwer Health, |c ©2015. | ||
| 300 | |a 1 online resource (xix, 287 pages) : |b color illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Handbook of Targeted Cancer Therapy; Contributors; Preface; Acknowledgments; Contents; Section 1 Targets by Organ Site; Abbreviations; Adrenocortical Carcinoma; Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct); Bladder Carcinoma (Urothelial Cancer); Brain Tumors; Glioblastoma/Malignant Gliomas; Medulloblastoma; Meningiomas; Other NF-Related Tumors; Breast Cancer; ER/PR+; HER2+; Triple-Negative/Basal/Metaplastic; Cervical Cancer; Colorectal Cancer (Adenocarcinoma); Esophageal Cancer (Squamous Cell); Gastric Cancer/Gastroesophageal Junction (Adenocarcinoma); Head and Neck Cancer. | |
| 505 | 8 | |a Squamous Cell-OropharynxSalivary Gland; Kidney (Renal Cell) Cancer; Liver Cancer (Hepatocellular); Leukemia; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Neoplasm; Lung Cancer (Non-Small Cell); Lymphoma; Melanoma; Multiple Myeloma; Ovarian Cancer; Pancreatic Cancer (Ductal Carcinoma); Prostate Cancer (Adenocarcinoma); Sarcoma (Gastrointestinal Stromal Tumors, GIST); Skin Cancer (Basal Cell); Testicular Cancer (Germ Cell Carcinoma); Thymoma and Thymic Carcinoma; Thyroid Cancer. | |
| 505 | 8 | |a Papillary and Follicular CarcinomaMedullary Carcinoma; Anaplastic Carcinoma; Uterine (Endometrial) Cancer; Section 2 Carcinogenesis from the Perspective of Targeted Therapy; Section 3 Molecular Targets and Pathways; Angiogenesis; Angiogenesis Regulators; Targeting HIF-1Ü; Receptor Tyrosine Kinases; VEGFR and Targeting VEGFR; FGFR and Targeting FGFR; PDGFR and Targeting PDGFR; TIE Receptors Signaling; TIE Receptors; IGF-1R and Insulin Receptor Signaling; IGF-1R and Insulin Receptor; TGFÜ/Ý Pathway; EGFR Family of Receptors; EGFR Ligands; EGFR Resistant and Sensitive Mutations; EGFR Inhibition. | |
| 505 | 8 | |a Targeting HER2HGF Receptors: MET; Targeting MET; RET Receptor; Targeting RET; KIT Receptor; ALK Receptor; ALK Alterations; G Protein-Coupled Receptor Pathways; RAS/MAPK Pathway; Targeting RAS; Targeting BRAF Mutations; Targeting MEK and MAPK; PI3K Pathway; Targeting PI3K Mutations; AKT Pathway; Targeting AKT Mutations; PTEN Alterations and TSC Mutations; Targeting mTORC1 Complex; Targeting mTORC2 Complex; JAK/STAT Pathway; Targeting JAK; Hedgehog Signaling Pathway; Notch Pathway; Wnt Pathway; SRC Pathway; NFmB Pathway; Death Receptors and Apoptosis; Cell Cycle Regulation; TP53; RB1. | |
| 505 | 8 | |a CDKN2A RegulationBRCA; BRCA and PARP; Aurora Kinases; Immunotherapy; Section 4 Targeted Therapy Agents; Abiraterone Acetate (Zytiga); ABT-199; Afatinib Dimaleate (Gilotrif); Afuresertib; Alemtuzumab (Campath-1h); Alisertib; Amg 208 and 337; Apatinib; Axitinib (Inlyta); Anetumab Ravtansine; Bevacizumab (Avastin); BI 811283; Bicalutamide (Casodex/Cosudex); Blinatumomab; BMS-936559; Bortezomib (Velcade); Bosutinib (Bosulif); Brentuximab Vedotin (Adcetris); Brivanib Alaninate; Buparlisib; BYL719; Cabozantinib (Cometriq); Carfilzomib (Kyprolis); Cediranib; Cetuximab (Erbitux); Cixutumumab. | |
| 520 | 8 | |a Make optimal use of the latest personalized therapeutic strategies with Handbook of Targeted Cancer Therapy! This concise, practical oncology reference examines more than 120 targeted therapy agents for which clinical trial data are available, and explains when and how you can use them to most effectively combat cancer. Approach clinical challenges from any direction with separate sections on Targets by Organ Site, Carcinogenesis from the Perspective of Targeted Therapy, Molecular Targets and Pathways, and Targeted Therapy Agents; find information easily thanks to a color-coded format and an intuitive organization; access the complete contents online and on mobile devices, with regular updates to include newly approved treatments and important state of the art cancer information for caregivers, researchers, other health care professionals, and even patients. Now with the print edition, enjoy the bundled interactive eBook edition, offering tablet, smartphone, or online access to: complete content with enhanced navigation; a powerful search tool that pulls results from content in the book, your notes, and even the web; cross-linked pages, references, and more for easy navigation; highlighting tool for easier reference of key content throughout the text; ability to take and share notes with friends and colleagues and quick-reference tabbing to save your favorite content for future use. | |
| 546 | |a English. | ||
| 650 | 0 | |a Cancer |x Chemotherapy |v Handbooks, manuals, etc. | |
| 650 | 0 | |a Antineoplastic agents |v Handbooks, manuals, etc. | |
| 650 | 0 | |a Drug targeting |v Handbooks, manuals, etc. | |
| 650 | 0 | |a Cancer |x Molecular aspects |v Handbooks, manuals, etc. | |
| 650 | 1 | 2 | |a Molecular Targeted Therapy |x methods |
| 650 | 1 | 2 | |a Neoplasms |x drug therapy |
| 650 | 2 | 2 | |a Antineoplastic Agents |x administration & dosage |
| 650 | 2 | 2 | |a Antineoplastic Agents |x antagonists & inhibitors |
| 650 | 2 | 2 | |a Antineoplastic Agents |x metabolism |
| 650 | 6 | |a Cancer |x Chimiothérapie |v Guides, manuels, etc. | |
| 650 | 6 | |a Anticancéreux |v Guides, manuels, etc. | |
| 650 | 6 | |a Médicaments |x Ciblage |v Guides, manuels, etc. | |
| 650 | 6 | |a Cancer |x Aspect moléculaire |v Guides, manuels, etc. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Antineoplastic agents |2 fast | |
| 650 | 7 | |a Cancer |x Chemotherapy |2 fast | |
| 650 | 7 | |a Cancer |x Molecular aspects |2 fast | |
| 650 | 7 | |a Drug targeting |2 fast | |
| 650 | 7 | |a Therapie |2 gnd |0 http://d-nb.info/gnd/4059798-2 | |
| 650 | 7 | |a Immuntherapie |2 gnd |0 http://d-nb.info/gnd/4026640-0 | |
| 650 | 7 | |a Krebs |g Medizin |2 gnd |0 http://d-nb.info/gnd/4073781-0 | |
| 650 | 7 | |a Onkologie |2 gnd |0 http://d-nb.info/gnd/4075658-0 | |
| 655 | 2 | |a Handbook | |
| 655 | 7 | |a manuals (instructional materials) |2 aat | |
| 655 | 7 | |a handbooks. |2 aat | |
| 655 | 7 | |a Handbooks and manuals |2 fast | |
| 655 | 7 | |a Handbooks and manuals. |2 lcgft |0 http://id.loc.gov/authorities/genreForms/gf2014026109 | |
| 655 | 7 | |a Guides et manuels. |2 rvmgf | |
| 700 | 1 | |a Karp, Daniel D., |e editor. |0 http://id.loc.gov/authorities/names/n2014186800 | |
| 700 | 1 | |a Falchook, Gerald S., |e editor. |0 http://id.loc.gov/authorities/names/n2014186801 | |
| 700 | 1 | |a Atkins, Johnique T., |e editor. |0 http://id.loc.gov/authorities/names/n2014186802 | |
| 776 | 0 | 8 | |i Print version: |t Handbook of targeted cancer therapy. |b 1st ed. |d Philadelphia : Wolters Kluwer Health, ©2015 |z 9781451193268 |w (DLC) 2014028967 |w (OCoLC)884541294 |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1473100 |3 Volltext |
| 938 | |a eLibro |b ELBO |n ELB167605 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL2035698 | ||
| 938 | |a EBSCOhost |b EBSC |n 1473100 | ||
| 938 | |a YBP Library Services |b YANK |n 13519248 | ||
| 938 | |a YBP Library Services |b YANK |n 12399329 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn904377433 |
|---|---|
| _version_ | 1816882305337131008 |
| adam_text | |
| any_adam_object | |
| author2 | Karp, Daniel D. Falchook, Gerald S. Atkins, Johnique T. |
| author2_role | edt edt edt |
| author2_variant | d d k dd ddk g s f gs gsf j t a jt jta |
| author_GND | http://id.loc.gov/authorities/names/n2014186800 http://id.loc.gov/authorities/names/n2014186801 http://id.loc.gov/authorities/names/n2014186802 |
| author_facet | Karp, Daniel D. Falchook, Gerald S. Atkins, Johnique T. |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC271 |
| callnumber-raw | RC271.C5 H36 2015 RC271.C5 |
| callnumber-search | RC271.C5 H36 2015 RC271.C5 |
| callnumber-sort | RC 3271 C5 H36 42015 |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | Handbook of Targeted Cancer Therapy; Contributors; Preface; Acknowledgments; Contents; Section 1 Targets by Organ Site; Abbreviations; Adrenocortical Carcinoma; Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct); Bladder Carcinoma (Urothelial Cancer); Brain Tumors; Glioblastoma/Malignant Gliomas; Medulloblastoma; Meningiomas; Other NF-Related Tumors; Breast Cancer; ER/PR+; HER2+; Triple-Negative/Basal/Metaplastic; Cervical Cancer; Colorectal Cancer (Adenocarcinoma); Esophageal Cancer (Squamous Cell); Gastric Cancer/Gastroesophageal Junction (Adenocarcinoma); Head and Neck Cancer. Squamous Cell-OropharynxSalivary Gland; Kidney (Renal Cell) Cancer; Liver Cancer (Hepatocellular); Leukemia; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Neoplasm; Lung Cancer (Non-Small Cell); Lymphoma; Melanoma; Multiple Myeloma; Ovarian Cancer; Pancreatic Cancer (Ductal Carcinoma); Prostate Cancer (Adenocarcinoma); Sarcoma (Gastrointestinal Stromal Tumors, GIST); Skin Cancer (Basal Cell); Testicular Cancer (Germ Cell Carcinoma); Thymoma and Thymic Carcinoma; Thyroid Cancer. Papillary and Follicular CarcinomaMedullary Carcinoma; Anaplastic Carcinoma; Uterine (Endometrial) Cancer; Section 2 Carcinogenesis from the Perspective of Targeted Therapy; Section 3 Molecular Targets and Pathways; Angiogenesis; Angiogenesis Regulators; Targeting HIF-1Ü; Receptor Tyrosine Kinases; VEGFR and Targeting VEGFR; FGFR and Targeting FGFR; PDGFR and Targeting PDGFR; TIE Receptors Signaling; TIE Receptors; IGF-1R and Insulin Receptor Signaling; IGF-1R and Insulin Receptor; TGFÜ/Ý Pathway; EGFR Family of Receptors; EGFR Ligands; EGFR Resistant and Sensitive Mutations; EGFR Inhibition. Targeting HER2HGF Receptors: MET; Targeting MET; RET Receptor; Targeting RET; KIT Receptor; ALK Receptor; ALK Alterations; G Protein-Coupled Receptor Pathways; RAS/MAPK Pathway; Targeting RAS; Targeting BRAF Mutations; Targeting MEK and MAPK; PI3K Pathway; Targeting PI3K Mutations; AKT Pathway; Targeting AKT Mutations; PTEN Alterations and TSC Mutations; Targeting mTORC1 Complex; Targeting mTORC2 Complex; JAK/STAT Pathway; Targeting JAK; Hedgehog Signaling Pathway; Notch Pathway; Wnt Pathway; SRC Pathway; NFmB Pathway; Death Receptors and Apoptosis; Cell Cycle Regulation; TP53; RB1. CDKN2A RegulationBRCA; BRCA and PARP; Aurora Kinases; Immunotherapy; Section 4 Targeted Therapy Agents; Abiraterone Acetate (Zytiga); ABT-199; Afatinib Dimaleate (Gilotrif); Afuresertib; Alemtuzumab (Campath-1h); Alisertib; Amg 208 and 337; Apatinib; Axitinib (Inlyta); Anetumab Ravtansine; Bevacizumab (Avastin); BI 811283; Bicalutamide (Casodex/Cosudex); Blinatumomab; BMS-936559; Bortezomib (Velcade); Bosutinib (Bosulif); Brentuximab Vedotin (Adcetris); Brivanib Alaninate; Buparlisib; BYL719; Cabozantinib (Cometriq); Carfilzomib (Kyprolis); Cediranib; Cetuximab (Erbitux); Cixutumumab. |
| ctrlnum | (OCoLC)904377433 |
| dewey-full | 616.99/4061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4061 RC271.C5 |
| dewey-search | 616.99/4061 RC271.C5 |
| dewey-sort | 3616.99 44061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 1st ed. |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>09015cam a2201045Ma 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn904377433</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">140722s2015 paua obf 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">OTZ</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">OTZ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">EBLCP</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">YDX</subfield><subfield code="d">N$T</subfield><subfield code="d">OCLCO</subfield><subfield code="d">UAB</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">D6H</subfield><subfield code="d">OCLCO</subfield><subfield code="d">AGLDB</subfield><subfield code="d">OCLCO</subfield><subfield code="d">IGB</subfield><subfield code="d">OCLCO</subfield><subfield code="d">CN8ML</subfield><subfield code="d">SNK</subfield><subfield code="d">INTCL</subfield><subfield code="d">OCLCO</subfield><subfield code="d">MHW</subfield><subfield code="d">BTN</subfield><subfield code="d">AUW</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VTS</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">AU@</subfield><subfield code="d">G3B</subfield><subfield code="d">S8I</subfield><subfield code="d">S8J</subfield><subfield code="d">S9I</subfield><subfield code="d">STF</subfield><subfield code="d">LOA</subfield><subfield code="d">MERUC</subfield><subfield code="d">SCB</subfield><subfield code="d">OCLCO</subfield><subfield code="d">VT2</subfield><subfield code="d">USU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">VLY</subfield><subfield code="d">DKU</subfield><subfield code="d">YDXCP</subfield><subfield code="d">QGK</subfield><subfield code="d">OCL</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">ELBRO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">101637430</subfield><subfield code="2">DNLM</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">899359538</subfield><subfield code="a">987351660</subfield><subfield code="a">987738124</subfield><subfield code="a">1072012677</subfield><subfield code="a">1103263051</subfield><subfield code="a">1162302923</subfield><subfield code="a">1228572739</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781451193268</subfield><subfield code="q">(alk. paper)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1451193262</subfield><subfield code="q">(alk. paper)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781469894584</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1469894580</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1451193262¡</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)904377433</subfield><subfield code="z">(OCoLC)899359538</subfield><subfield code="z">(OCoLC)987351660</subfield><subfield code="z">(OCoLC)987738124</subfield><subfield code="z">(OCoLC)1072012677</subfield><subfield code="z">(OCoLC)1103263051</subfield><subfield code="z">(OCoLC)1162302923</subfield><subfield code="z">(OCoLC)1228572739</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC271.C5</subfield><subfield code="b">H36 2015</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC271.C5</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QZ 39</subfield><subfield code="b">H23658 2015</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA</subfield><subfield code="x">039000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">014000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">022000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">112000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">045000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.99/4061</subfield><subfield code="2">23</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">RC271.C5</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Handbook of targeted cancer therapy /</subfield><subfield code="c">editors, Daniel D. Karp, Gerald S. Falchook ; assistant editor, Johnique T. Atkins.</subfield></datafield><datafield tag="246" ind1="3" ind2=" "><subfield code="a">Targeted cancer therapy</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Philadelphia :</subfield><subfield code="b">Wolters Kluwer Health,</subfield><subfield code="c">©2015.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xix, 287 pages) :</subfield><subfield code="b">color illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Handbook of Targeted Cancer Therapy; Contributors; Preface; Acknowledgments; Contents; Section 1 Targets by Organ Site; Abbreviations; Adrenocortical Carcinoma; Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct); Bladder Carcinoma (Urothelial Cancer); Brain Tumors; Glioblastoma/Malignant Gliomas; Medulloblastoma; Meningiomas; Other NF-Related Tumors; Breast Cancer; ER/PR+; HER2+; Triple-Negative/Basal/Metaplastic; Cervical Cancer; Colorectal Cancer (Adenocarcinoma); Esophageal Cancer (Squamous Cell); Gastric Cancer/Gastroesophageal Junction (Adenocarcinoma); Head and Neck Cancer.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Squamous Cell-OropharynxSalivary Gland; Kidney (Renal Cell) Cancer; Liver Cancer (Hepatocellular); Leukemia; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Neoplasm; Lung Cancer (Non-Small Cell); Lymphoma; Melanoma; Multiple Myeloma; Ovarian Cancer; Pancreatic Cancer (Ductal Carcinoma); Prostate Cancer (Adenocarcinoma); Sarcoma (Gastrointestinal Stromal Tumors, GIST); Skin Cancer (Basal Cell); Testicular Cancer (Germ Cell Carcinoma); Thymoma and Thymic Carcinoma; Thyroid Cancer.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Papillary and Follicular CarcinomaMedullary Carcinoma; Anaplastic Carcinoma; Uterine (Endometrial) Cancer; Section 2 Carcinogenesis from the Perspective of Targeted Therapy; Section 3 Molecular Targets and Pathways; Angiogenesis; Angiogenesis Regulators; Targeting HIF-1Ü; Receptor Tyrosine Kinases; VEGFR and Targeting VEGFR; FGFR and Targeting FGFR; PDGFR and Targeting PDGFR; TIE Receptors Signaling; TIE Receptors; IGF-1R and Insulin Receptor Signaling; IGF-1R and Insulin Receptor; TGFÜ/Ý Pathway; EGFR Family of Receptors; EGFR Ligands; EGFR Resistant and Sensitive Mutations; EGFR Inhibition.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Targeting HER2HGF Receptors: MET; Targeting MET; RET Receptor; Targeting RET; KIT Receptor; ALK Receptor; ALK Alterations; G Protein-Coupled Receptor Pathways; RAS/MAPK Pathway; Targeting RAS; Targeting BRAF Mutations; Targeting MEK and MAPK; PI3K Pathway; Targeting PI3K Mutations; AKT Pathway; Targeting AKT Mutations; PTEN Alterations and TSC Mutations; Targeting mTORC1 Complex; Targeting mTORC2 Complex; JAK/STAT Pathway; Targeting JAK; Hedgehog Signaling Pathway; Notch Pathway; Wnt Pathway; SRC Pathway; NFmB Pathway; Death Receptors and Apoptosis; Cell Cycle Regulation; TP53; RB1.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">CDKN2A RegulationBRCA; BRCA and PARP; Aurora Kinases; Immunotherapy; Section 4 Targeted Therapy Agents; Abiraterone Acetate (Zytiga); ABT-199; Afatinib Dimaleate (Gilotrif); Afuresertib; Alemtuzumab (Campath-1h); Alisertib; Amg 208 and 337; Apatinib; Axitinib (Inlyta); Anetumab Ravtansine; Bevacizumab (Avastin); BI 811283; Bicalutamide (Casodex/Cosudex); Blinatumomab; BMS-936559; Bortezomib (Velcade); Bosutinib (Bosulif); Brentuximab Vedotin (Adcetris); Brivanib Alaninate; Buparlisib; BYL719; Cabozantinib (Cometriq); Carfilzomib (Kyprolis); Cediranib; Cetuximab (Erbitux); Cixutumumab.</subfield></datafield><datafield tag="520" ind1="8" ind2=" "><subfield code="a">Make optimal use of the latest personalized therapeutic strategies with Handbook of Targeted Cancer Therapy! This concise, practical oncology reference examines more than 120 targeted therapy agents for which clinical trial data are available, and explains when and how you can use them to most effectively combat cancer. Approach clinical challenges from any direction with separate sections on Targets by Organ Site, Carcinogenesis from the Perspective of Targeted Therapy, Molecular Targets and Pathways, and Targeted Therapy Agents; find information easily thanks to a color-coded format and an intuitive organization; access the complete contents online and on mobile devices, with regular updates to include newly approved treatments and important state of the art cancer information for caregivers, researchers, other health care professionals, and even patients. Now with the print edition, enjoy the bundled interactive eBook edition, offering tablet, smartphone, or online access to: complete content with enhanced navigation; a powerful search tool that pulls results from content in the book, your notes, and even the web; cross-linked pages, references, and more for easy navigation; highlighting tool for easier reference of key content throughout the text; ability to take and share notes with friends and colleagues and quick-reference tabbing to save your favorite content for future use.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer</subfield><subfield code="x">Chemotherapy</subfield><subfield code="v">Handbooks, manuals, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Antineoplastic agents</subfield><subfield code="v">Handbooks, manuals, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug targeting</subfield><subfield code="v">Handbooks, manuals, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer</subfield><subfield code="x">Molecular aspects</subfield><subfield code="v">Handbooks, manuals, etc.</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Molecular Targeted Therapy</subfield><subfield code="x">methods</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">administration & dosage</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">antagonists & inhibitors</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">metabolism</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Cancer</subfield><subfield code="x">Chimiothérapie</subfield><subfield code="v">Guides, manuels, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Anticancéreux</subfield><subfield code="v">Guides, manuels, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Ciblage</subfield><subfield code="v">Guides, manuels, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Cancer</subfield><subfield code="x">Aspect moléculaire</subfield><subfield code="v">Guides, manuels, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS</subfield><subfield code="x">Diseases</subfield><subfield code="x">General.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Clinical Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Diseases.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Evidence-Based Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Internal Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antineoplastic agents</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer</subfield><subfield code="x">Chemotherapy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer</subfield><subfield code="x">Molecular aspects</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug targeting</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapie</subfield><subfield code="2">gnd</subfield><subfield code="0">http://d-nb.info/gnd/4059798-2</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immuntherapie</subfield><subfield code="2">gnd</subfield><subfield code="0">http://d-nb.info/gnd/4026640-0</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="2">gnd</subfield><subfield code="0">http://d-nb.info/gnd/4073781-0</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Onkologie</subfield><subfield code="2">gnd</subfield><subfield code="0">http://d-nb.info/gnd/4075658-0</subfield></datafield><datafield tag="655" ind1=" " ind2="2"><subfield code="a">Handbook</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">manuals (instructional materials)</subfield><subfield code="2">aat</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">handbooks.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Handbooks and manuals</subfield><subfield code="2">fast</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Handbooks and manuals.</subfield><subfield code="2">lcgft</subfield><subfield code="0">http://id.loc.gov/authorities/genreForms/gf2014026109</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Guides et manuels.</subfield><subfield code="2">rvmgf</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karp, Daniel D.,</subfield><subfield code="e">editor.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2014186800</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Falchook, Gerald S.,</subfield><subfield code="e">editor.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2014186801</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Atkins, Johnique T.,</subfield><subfield code="e">editor.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2014186802</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Handbook of targeted cancer therapy.</subfield><subfield code="b">1st ed.</subfield><subfield code="d">Philadelphia : Wolters Kluwer Health, ©2015</subfield><subfield code="z">9781451193268</subfield><subfield code="w">(DLC) 2014028967</subfield><subfield code="w">(OCoLC)884541294</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1473100</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">eLibro</subfield><subfield code="b">ELBO</subfield><subfield code="n">ELB167605</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL2035698</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1473100</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">13519248</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">12399329</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| genre | Handbook manuals (instructional materials) aat handbooks. aat Handbooks and manuals fast Handbooks and manuals. lcgft http://id.loc.gov/authorities/genreForms/gf2014026109 Guides et manuels. rvmgf |
| genre_facet | Handbook manuals (instructional materials) handbooks. Handbooks and manuals Handbooks and manuals. Guides et manuels. |
| id | ZDB-4-EBA-ocn904377433 |
| illustrated | Illustrated |
| indexdate | 2024-11-27T13:26:30Z |
| institution | BVB |
| isbn | 9781451193268 1451193262 9781469894584 1469894580 |
| language | English |
| oclc_num | 904377433 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (xix, 287 pages) : color illustrations |
| psigel | ZDB-4-EBA |
| publishDate | 2015 |
| publishDateSearch | 2015 |
| publishDateSort | 2015 |
| publisher | Wolters Kluwer Health, |
| record_format | marc |
| spelling | Handbook of targeted cancer therapy / editors, Daniel D. Karp, Gerald S. Falchook ; assistant editor, Johnique T. Atkins. Targeted cancer therapy 1st ed. Philadelphia : Wolters Kluwer Health, ©2015. 1 online resource (xix, 287 pages) : color illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Includes bibliographical references and index. Handbook of Targeted Cancer Therapy; Contributors; Preface; Acknowledgments; Contents; Section 1 Targets by Organ Site; Abbreviations; Adrenocortical Carcinoma; Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct); Bladder Carcinoma (Urothelial Cancer); Brain Tumors; Glioblastoma/Malignant Gliomas; Medulloblastoma; Meningiomas; Other NF-Related Tumors; Breast Cancer; ER/PR+; HER2+; Triple-Negative/Basal/Metaplastic; Cervical Cancer; Colorectal Cancer (Adenocarcinoma); Esophageal Cancer (Squamous Cell); Gastric Cancer/Gastroesophageal Junction (Adenocarcinoma); Head and Neck Cancer. Squamous Cell-OropharynxSalivary Gland; Kidney (Renal Cell) Cancer; Liver Cancer (Hepatocellular); Leukemia; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Neoplasm; Lung Cancer (Non-Small Cell); Lymphoma; Melanoma; Multiple Myeloma; Ovarian Cancer; Pancreatic Cancer (Ductal Carcinoma); Prostate Cancer (Adenocarcinoma); Sarcoma (Gastrointestinal Stromal Tumors, GIST); Skin Cancer (Basal Cell); Testicular Cancer (Germ Cell Carcinoma); Thymoma and Thymic Carcinoma; Thyroid Cancer. Papillary and Follicular CarcinomaMedullary Carcinoma; Anaplastic Carcinoma; Uterine (Endometrial) Cancer; Section 2 Carcinogenesis from the Perspective of Targeted Therapy; Section 3 Molecular Targets and Pathways; Angiogenesis; Angiogenesis Regulators; Targeting HIF-1Ü; Receptor Tyrosine Kinases; VEGFR and Targeting VEGFR; FGFR and Targeting FGFR; PDGFR and Targeting PDGFR; TIE Receptors Signaling; TIE Receptors; IGF-1R and Insulin Receptor Signaling; IGF-1R and Insulin Receptor; TGFÜ/Ý Pathway; EGFR Family of Receptors; EGFR Ligands; EGFR Resistant and Sensitive Mutations; EGFR Inhibition. Targeting HER2HGF Receptors: MET; Targeting MET; RET Receptor; Targeting RET; KIT Receptor; ALK Receptor; ALK Alterations; G Protein-Coupled Receptor Pathways; RAS/MAPK Pathway; Targeting RAS; Targeting BRAF Mutations; Targeting MEK and MAPK; PI3K Pathway; Targeting PI3K Mutations; AKT Pathway; Targeting AKT Mutations; PTEN Alterations and TSC Mutations; Targeting mTORC1 Complex; Targeting mTORC2 Complex; JAK/STAT Pathway; Targeting JAK; Hedgehog Signaling Pathway; Notch Pathway; Wnt Pathway; SRC Pathway; NFmB Pathway; Death Receptors and Apoptosis; Cell Cycle Regulation; TP53; RB1. CDKN2A RegulationBRCA; BRCA and PARP; Aurora Kinases; Immunotherapy; Section 4 Targeted Therapy Agents; Abiraterone Acetate (Zytiga); ABT-199; Afatinib Dimaleate (Gilotrif); Afuresertib; Alemtuzumab (Campath-1h); Alisertib; Amg 208 and 337; Apatinib; Axitinib (Inlyta); Anetumab Ravtansine; Bevacizumab (Avastin); BI 811283; Bicalutamide (Casodex/Cosudex); Blinatumomab; BMS-936559; Bortezomib (Velcade); Bosutinib (Bosulif); Brentuximab Vedotin (Adcetris); Brivanib Alaninate; Buparlisib; BYL719; Cabozantinib (Cometriq); Carfilzomib (Kyprolis); Cediranib; Cetuximab (Erbitux); Cixutumumab. Make optimal use of the latest personalized therapeutic strategies with Handbook of Targeted Cancer Therapy! This concise, practical oncology reference examines more than 120 targeted therapy agents for which clinical trial data are available, and explains when and how you can use them to most effectively combat cancer. Approach clinical challenges from any direction with separate sections on Targets by Organ Site, Carcinogenesis from the Perspective of Targeted Therapy, Molecular Targets and Pathways, and Targeted Therapy Agents; find information easily thanks to a color-coded format and an intuitive organization; access the complete contents online and on mobile devices, with regular updates to include newly approved treatments and important state of the art cancer information for caregivers, researchers, other health care professionals, and even patients. Now with the print edition, enjoy the bundled interactive eBook edition, offering tablet, smartphone, or online access to: complete content with enhanced navigation; a powerful search tool that pulls results from content in the book, your notes, and even the web; cross-linked pages, references, and more for easy navigation; highlighting tool for easier reference of key content throughout the text; ability to take and share notes with friends and colleagues and quick-reference tabbing to save your favorite content for future use. English. Cancer Chemotherapy Handbooks, manuals, etc. Antineoplastic agents Handbooks, manuals, etc. Drug targeting Handbooks, manuals, etc. Cancer Molecular aspects Handbooks, manuals, etc. Molecular Targeted Therapy methods Neoplasms drug therapy Antineoplastic Agents administration & dosage Antineoplastic Agents antagonists & inhibitors Antineoplastic Agents metabolism Cancer Chimiothérapie Guides, manuels, etc. Anticancéreux Guides, manuels, etc. Médicaments Ciblage Guides, manuels, etc. Cancer Aspect moléculaire Guides, manuels, etc. HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Antineoplastic agents fast Cancer Chemotherapy fast Cancer Molecular aspects fast Drug targeting fast Therapie gnd http://d-nb.info/gnd/4059798-2 Immuntherapie gnd http://d-nb.info/gnd/4026640-0 Krebs Medizin gnd http://d-nb.info/gnd/4073781-0 Onkologie gnd http://d-nb.info/gnd/4075658-0 Handbook manuals (instructional materials) aat handbooks. aat Handbooks and manuals fast Handbooks and manuals. lcgft http://id.loc.gov/authorities/genreForms/gf2014026109 Guides et manuels. rvmgf Karp, Daniel D., editor. http://id.loc.gov/authorities/names/n2014186800 Falchook, Gerald S., editor. http://id.loc.gov/authorities/names/n2014186801 Atkins, Johnique T., editor. http://id.loc.gov/authorities/names/n2014186802 Print version: Handbook of targeted cancer therapy. 1st ed. Philadelphia : Wolters Kluwer Health, ©2015 9781451193268 (DLC) 2014028967 (OCoLC)884541294 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1473100 Volltext |
| spellingShingle | Handbook of targeted cancer therapy / Handbook of Targeted Cancer Therapy; Contributors; Preface; Acknowledgments; Contents; Section 1 Targets by Organ Site; Abbreviations; Adrenocortical Carcinoma; Biliary Tract Adenocarcinoma (Gallbladder, Bile Duct); Bladder Carcinoma (Urothelial Cancer); Brain Tumors; Glioblastoma/Malignant Gliomas; Medulloblastoma; Meningiomas; Other NF-Related Tumors; Breast Cancer; ER/PR+; HER2+; Triple-Negative/Basal/Metaplastic; Cervical Cancer; Colorectal Cancer (Adenocarcinoma); Esophageal Cancer (Squamous Cell); Gastric Cancer/Gastroesophageal Junction (Adenocarcinoma); Head and Neck Cancer. Squamous Cell-OropharynxSalivary Gland; Kidney (Renal Cell) Cancer; Liver Cancer (Hepatocellular); Leukemia; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Neoplasm; Lung Cancer (Non-Small Cell); Lymphoma; Melanoma; Multiple Myeloma; Ovarian Cancer; Pancreatic Cancer (Ductal Carcinoma); Prostate Cancer (Adenocarcinoma); Sarcoma (Gastrointestinal Stromal Tumors, GIST); Skin Cancer (Basal Cell); Testicular Cancer (Germ Cell Carcinoma); Thymoma and Thymic Carcinoma; Thyroid Cancer. Papillary and Follicular CarcinomaMedullary Carcinoma; Anaplastic Carcinoma; Uterine (Endometrial) Cancer; Section 2 Carcinogenesis from the Perspective of Targeted Therapy; Section 3 Molecular Targets and Pathways; Angiogenesis; Angiogenesis Regulators; Targeting HIF-1Ü; Receptor Tyrosine Kinases; VEGFR and Targeting VEGFR; FGFR and Targeting FGFR; PDGFR and Targeting PDGFR; TIE Receptors Signaling; TIE Receptors; IGF-1R and Insulin Receptor Signaling; IGF-1R and Insulin Receptor; TGFÜ/Ý Pathway; EGFR Family of Receptors; EGFR Ligands; EGFR Resistant and Sensitive Mutations; EGFR Inhibition. Targeting HER2HGF Receptors: MET; Targeting MET; RET Receptor; Targeting RET; KIT Receptor; ALK Receptor; ALK Alterations; G Protein-Coupled Receptor Pathways; RAS/MAPK Pathway; Targeting RAS; Targeting BRAF Mutations; Targeting MEK and MAPK; PI3K Pathway; Targeting PI3K Mutations; AKT Pathway; Targeting AKT Mutations; PTEN Alterations and TSC Mutations; Targeting mTORC1 Complex; Targeting mTORC2 Complex; JAK/STAT Pathway; Targeting JAK; Hedgehog Signaling Pathway; Notch Pathway; Wnt Pathway; SRC Pathway; NFmB Pathway; Death Receptors and Apoptosis; Cell Cycle Regulation; TP53; RB1. CDKN2A RegulationBRCA; BRCA and PARP; Aurora Kinases; Immunotherapy; Section 4 Targeted Therapy Agents; Abiraterone Acetate (Zytiga); ABT-199; Afatinib Dimaleate (Gilotrif); Afuresertib; Alemtuzumab (Campath-1h); Alisertib; Amg 208 and 337; Apatinib; Axitinib (Inlyta); Anetumab Ravtansine; Bevacizumab (Avastin); BI 811283; Bicalutamide (Casodex/Cosudex); Blinatumomab; BMS-936559; Bortezomib (Velcade); Bosutinib (Bosulif); Brentuximab Vedotin (Adcetris); Brivanib Alaninate; Buparlisib; BYL719; Cabozantinib (Cometriq); Carfilzomib (Kyprolis); Cediranib; Cetuximab (Erbitux); Cixutumumab. Cancer Chemotherapy Handbooks, manuals, etc. Antineoplastic agents Handbooks, manuals, etc. Drug targeting Handbooks, manuals, etc. Cancer Molecular aspects Handbooks, manuals, etc. Molecular Targeted Therapy methods Neoplasms drug therapy Antineoplastic Agents administration & dosage Antineoplastic Agents antagonists & inhibitors Antineoplastic Agents metabolism Cancer Chimiothérapie Guides, manuels, etc. Anticancéreux Guides, manuels, etc. Médicaments Ciblage Guides, manuels, etc. Cancer Aspect moléculaire Guides, manuels, etc. HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Antineoplastic agents fast Cancer Chemotherapy fast Cancer Molecular aspects fast Drug targeting fast Therapie gnd http://d-nb.info/gnd/4059798-2 Immuntherapie gnd http://d-nb.info/gnd/4026640-0 Krebs Medizin gnd http://d-nb.info/gnd/4073781-0 Onkologie gnd http://d-nb.info/gnd/4075658-0 |
| subject_GND | http://d-nb.info/gnd/4059798-2 http://d-nb.info/gnd/4026640-0 http://d-nb.info/gnd/4073781-0 http://d-nb.info/gnd/4075658-0 http://id.loc.gov/authorities/genreForms/gf2014026109 |
| title | Handbook of targeted cancer therapy / |
| title_alt | Targeted cancer therapy |
| title_auth | Handbook of targeted cancer therapy / |
| title_exact_search | Handbook of targeted cancer therapy / |
| title_full | Handbook of targeted cancer therapy / editors, Daniel D. Karp, Gerald S. Falchook ; assistant editor, Johnique T. Atkins. |
| title_fullStr | Handbook of targeted cancer therapy / editors, Daniel D. Karp, Gerald S. Falchook ; assistant editor, Johnique T. Atkins. |
| title_full_unstemmed | Handbook of targeted cancer therapy / editors, Daniel D. Karp, Gerald S. Falchook ; assistant editor, Johnique T. Atkins. |
| title_short | Handbook of targeted cancer therapy / |
| title_sort | handbook of targeted cancer therapy |
| topic | Cancer Chemotherapy Handbooks, manuals, etc. Antineoplastic agents Handbooks, manuals, etc. Drug targeting Handbooks, manuals, etc. Cancer Molecular aspects Handbooks, manuals, etc. Molecular Targeted Therapy methods Neoplasms drug therapy Antineoplastic Agents administration & dosage Antineoplastic Agents antagonists & inhibitors Antineoplastic Agents metabolism Cancer Chimiothérapie Guides, manuels, etc. Anticancéreux Guides, manuels, etc. Médicaments Ciblage Guides, manuels, etc. Cancer Aspect moléculaire Guides, manuels, etc. HEALTH & FITNESS Diseases General. bisacsh MEDICAL Clinical Medicine. bisacsh MEDICAL Diseases. bisacsh MEDICAL Evidence-Based Medicine. bisacsh MEDICAL Internal Medicine. bisacsh Antineoplastic agents fast Cancer Chemotherapy fast Cancer Molecular aspects fast Drug targeting fast Therapie gnd http://d-nb.info/gnd/4059798-2 Immuntherapie gnd http://d-nb.info/gnd/4026640-0 Krebs Medizin gnd http://d-nb.info/gnd/4073781-0 Onkologie gnd http://d-nb.info/gnd/4075658-0 |
| topic_facet | Cancer Chemotherapy Handbooks, manuals, etc. Antineoplastic agents Handbooks, manuals, etc. Drug targeting Handbooks, manuals, etc. Cancer Molecular aspects Handbooks, manuals, etc. Molecular Targeted Therapy methods Neoplasms drug therapy Antineoplastic Agents administration & dosage Antineoplastic Agents antagonists & inhibitors Antineoplastic Agents metabolism Cancer Chimiothérapie Guides, manuels, etc. Anticancéreux Guides, manuels, etc. Médicaments Ciblage Guides, manuels, etc. Cancer Aspect moléculaire Guides, manuels, etc. HEALTH & FITNESS Diseases General. MEDICAL Clinical Medicine. MEDICAL Diseases. MEDICAL Evidence-Based Medicine. MEDICAL Internal Medicine. Antineoplastic agents Cancer Chemotherapy Cancer Molecular aspects Drug targeting Therapie Immuntherapie Krebs Medizin Onkologie Handbook manuals (instructional materials) handbooks. Handbooks and manuals Handbooks and manuals. Guides et manuels. |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1473100 |
| work_keys_str_mv | AT karpdanield handbookoftargetedcancertherapy AT falchookgeralds handbookoftargetedcancertherapy AT atkinsjohniquet handbookoftargetedcancertherapy AT karpdanield targetedcancertherapy AT falchookgeralds targetedcancertherapy AT atkinsjohniquet targetedcancertherapy |